Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cerebrovascular disorders; Venous thromboembolism
- Focus Pharmacokinetics
- Acronyms RivaMoS-2
- 31 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Oct 2014 Planned End Date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 08 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.